The increased CTA repertoire after low-dose 5-aza could be responsible for the observed changes in the IFN-γ signature and CD274 expression in participant 11, which was accompanied by a 20% reduction in the proportion of cancer cells in the TME after 5-aza treatment. This evidence concerns the gene CD274 and cancer.